Systemic inhibition of TGF‐β signaling can stimulate cell proliferation and enhance tumor response, thereby limiting its clinical application.[43] Therefore, targeting HSC‐specific factors that regulate TGF‐β signaling presents a potential avenue for effective and safe treatments of liver fibrosis. Here, TGFB1 is linked to neoplasm.